Clinical Trial: Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9

U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07678775) titled 'Open-Label Extension Study of BBP-418 (Ribitol) for LGMD2I/R9' on June 25.

Brief Summary: This is an open-label extension (rollover) study designed to evaluate the long-term safety and efficacy of BBP-418 (ribitol) in participants with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9) who have previously participated in Study MLB-01-005 (Fortify).

Participants will receive BBP-418 administered orally at protocol-defined doses and schedules. The study will assess long-term safety through monitoring of adverse events, clinical laboratory evaluations, and other safety assessments. Efficacy will be evaluated using functional measure...